Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

The Phase 3 PAPILLON study demonstrated that RYBREVANT with carboplatin and pemetrexed significantly enhances progression-free survival in NSCLC patients with EGFR exon 20 insertion mutations.